Prediction
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
- Participants must have a pathologic diagnosis of classical Hodgkin lymphoma (cHL) who are relapsed or refractory with one of the following:
i) Autologous stem cell transplant (ASCT) ineligible patients.
ii) Patients after failure of ASCT.
- Must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter and avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan.
- Participants must not have received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody.
Exclusion Criteria:
- Known central nervous system lymphoma.
- Participants with nodular lymphocyte-predominant Hodgkin lymphoma (HL).
- Participants with known history of pancreatitis or progressive multifocal leukoencephalopathy (PML).
- Participants with evidence of active brain metastases on brain imaging (i.e., MRI or contrast CT).
- Participants who have received prior allogeneic transplant.
- Participants who are BV refractory as identified by a failure to achieve a PR or CR, relapse, or progression within 3 months of receiving BV treatment.
- Participants with any positive test result for hepatitis B virus or hepatitis C virus indicating presence of virus.
- Participants with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- Participants who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
- Females who are pregnant or breastfeeding.